medmix has launched FleXa, a customisable syringe platform for single-component dental materials. The Swiss company's new system offers manufacturers over 150 medical-grade colours, custom colour matching, and design options including custom shapes and foil printing. The platform features a patent-pending drip-reducing plunger design to minimise material waste, a 360° rotatable Grip Plate for improved ergonomics, and a silicone oil-free system. FleXa comes in four volumes: 0.75 mL, 1 mL, 2 mL, and 3 mL, with shared outer dimensions and compatible accessories. CEO René Willi said the platform helps dental manufacturers differentiate whilst simplifying their supply chain. The system is compatible with over 60 medmix Dispensing Tips and can be delivered preassembled or unassembled to suit different production setups.

Medmix: rsquo; Drug Delivery ("Haselmeier") highlights self-injection PiccoJect(TM) platform as innovation for high-viscosity drugs. medmix' Drug Delivery ("Haselmeier") showcased the proven innovation behind its PiccoJect(TM) platform for high-viscosity drugs at the international conferences PDA Universe in Vienna and PODD in Boston. PiccoJect(TM) features a novel parallel spring mechanism that enables the delivery of both high- and low-viscosity formulations from a single, compact platform. This innovative design allows for precise and reliable adjustment of injection force, accommodating a broad range of drug viscosities while ensuring patient comfort and device reliability. The parallel spring layout also results in a rectangular cross section, which human factors studies have demonstrated to be more comfortable for users. Additionally, the design enables a large wraparound viewing window that allows patients to perform visual drug inspection and monitor injection progress with greater ease. PiccoJect(TM) is compatible with any standard 1 mL long or 2.25 mL prefilled syringe, enabling pharmaceutical companies to implement the device without requiring modifications to their existing filling operations. "The self-injection devices market is experiencing rapid expansion, which is driving pharmaceutical companies to find new ways to deliver increasingly complex drugs in patient-friendly formats," said Dr. Oliver Haferbeck, Head of Business Unit Drug Delivery, "By developing breakthrough solutions like PiccoJect(TM), we are strengthening medmix' position in high-growth healthcare markets and delivering the innovation our pharmaceutical partners need to bring successful therapies to patients." Since its introduction, PiccoJect(TM) has received international design awards for its ergonomic shape and innovative design. The device's simple construction of only eight parts, made with durable unfilled and bio-based polymers support efficient manufacturing and sustainability efforts. Pharmaceutical companies and industry experts value the distinct advantages the product platform provides in combination with medmix Drug Delivery expertise. medmix is a global leader in high-precision delivery devices, with leading positions in healthcare, consumer and industrial end-markets. Our customers benefit from our dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 14 production sites worldwide together with our highly motivated and experienced team of nearly 2'700 employees are at service of our customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). https://www.medmix.swiss This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein. Medmix Ltd. published this content on November 20, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 20, 2025 at 08:21 UTC.